Chemed Corporation, the company behind the Vitas hospice care network and the Roto-Rooter plumbing and drain-cleaning service, saw its shares climb after BofA Securities flagged a third-quarter earnings beat and a full-year guidance raise that points to continued strength at its end-of-life care business.
The Cincinnati-based firm, which operates in two very different corners of the economy—health care services and home maintenance—reported results that came in ahead of Wall Street's expectations. BofA, one of the largest U.S. banks, said Chemed's third-quarter earnings before interest, taxes, depreciation, and amortization (EBITDA) were roughly 2% above consensus, while earnings per share (EPS) were about 5% higher.
On its own, that kind of beat might justify a modest bump to the company's outlook. But BofA's analysis suggests the guidance raise is more meaningful than the headline numbers alone would suggest.
A guidance raise that signals more than a good quarter
At the midpoint, Chemed's increased full-year guidance equates to roughly $0.40 per share, or about $7 million in pretax profit. That is more than double the approximately $3 million EBITDA beat versus consensus for the quarter. In other words, the company is not just acknowledging a strong three months—it is signaling that the momentum is expected to carry into the final quarter of the year.
For investors, this distinction matters. When a company raises guidance by more than it beat estimates in the latest quarter, it often suggests the earnings “base” is moving higher, not just that one quarter was lucky. That tends to flow through to analyst models: forward EPS estimates get revised up, and the stock can reprice around whichever business line appears to be driving the step-up.
Here, the driver is clearly Vitas, Chemed's hospice unit, which provides palliative and end-of-life care to patients in their homes or in hospice facilities. Hospice care is a growing segment of the U.S. health care system, driven by an aging population and a shift toward more home-based care. Vitas has been a consistent growth engine for Chemed, and the third quarter appears to have been no exception.
Roto-Rooter's role is smaller than it seems
Chemed also recently completed a franchise acquisition for its Roto-Rooter business, which provides plumbing, drain cleaning, and water restoration services. BofA noted that this acquisition is expected to add less than $1 million of EBITDA—a relatively small amount in the context of Chemed's overall profitability.
That means the bigger story is Vitas offsetting ongoing softness at Roto-Rooter. The plumbing and home-services side of the business has faced headwinds, possibly due to softer consumer spending on discretionary home repairs or seasonal factors. But the strength at Vitas is more than making up for it.
For investors, this is a useful reminder that Chemed is really two businesses in one. The market often values the sum of the parts, and when one division is outperforming while the other lags, the overall picture can be more nuanced than a single earnings number suggests.
What it means for investors
BofA's $0.40 per-share uplift shifts attention to Vitas' fourth-quarter run rate. If the hospice unit continues to grow at the pace implied by the guidance, it could support further upward revisions to earnings estimates in the coming months.
With less than $1 million of expected EBITDA coming from the Roto-Rooter deal, day-to-day trading and valuation assumptions are likely to hinge more on Vitas trends than on the acquisition or near-term plumbing results. That means investors should watch for any signs of a slowdown in hospice admissions or reimbursement changes, which could affect the unit's trajectory.
Chemed's results also come amid a broader earnings season where several companies have raised guidance. For example, BASF lifted its 2026 outlook after a strong quarter, and Phillips 66 posted a record quarter on tight fuel markets. While those are different industries, the pattern of companies signaling confidence in the months ahead is a positive sign for the overall economy.
For everyday investors, the key takeaway is that Chemed's guidance raise is a signal of management's confidence in the business, particularly the hospice segment. It's not a recommendation to buy or sell the stock, but it does suggest that the company's growth story is intact, and that the market may be paying more attention to Vitas than to Roto-Rooter in the near term.
As always, it's worth remembering that guidance is just an estimate, and actual results can vary. But when a company raises its outlook by more than it beat expectations, it's often a sign that the underlying business is gaining momentum—and that's something investors tend to reward.
